The next-generation mTOR inhibitor, Rapalink-1, combined with sunitinib, produced a better therapeutic response in RCC.109 PIK3CA inhibitors can theoretically block the PI3K/AKT pathway, but their clinical effectiveness in combination with TKIs was not assessed yet. This evidence concerns the gene PIK3CA and renal cell carcinoma.